Stockscreener 앱 받기
153.29
1.73%
2.61
시장 영업 전:
152.01
-1.28
-0.84%
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Pacer Advisors Inc. Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 146,105 Shares of Stock - MarketBeat
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results - Victoria Advocate
Neurocrine Biosciences director sells shares worth $21.8 million - MSN
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges By Investing.com - Investing.com South Africa
Neurocrine Biosciences director sells shares worth $21.8 million By Investing.com - Investing.com Australia
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges - Investing.com
Prentiss Smith & Co. Inc. Invests $650,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal - MSN
Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder - Marketscreener.com
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights - Yahoo Finance
Neurocrine revamps osavampator deal with Takeda - The Pharma Letter
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal By Investing.com - Investing.com Nigeria
Game-Changing Depression Drug Enters Final Testing PhaseCould Help Millions Where Others Failed - StockTitan
Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences - MarketWatch
Neurocrine Amends Collaboration with Takeda on Osavampator -January 27, 2025 at 05:30 pm EST - Marketscreener.com
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator - Marketscreener.com
Where are the Opportunities in (NBIX) - Stock Traders Daily
Wedbush Forecasts Weaker Earnings for Neurocrine Biosciences - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Increased by Harel Insurance Investments & Financial Services Ltd. - MarketBeat
Daymark Wealth Partners LLC Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - MarketBeat
Andrew Ratz, Ph.D., Appointed Senior Vice President of Drug Development at Neurocrine Biosciences - citybiz
Neurocrine appoints Andrew Ratz as senior VP - The Pharma Letter
Neurocrine Biosciences Appoints SVP of Drug Development, Delivery and Device - Contract Pharma
2,735 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by HB Wealth Management LLC - MarketBeat
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device - Financial Times
Dyskinesia Pipeline 2024: Latest FDA Approvals, Clinical - openPR
Whalen Wealth Management Inc. Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine backs CAH-focused supplement in JCEM - MSN
Neurocrine backs CAH-focused supplement in JCEM By Investing.com - Investing.com Australia
Brokers Set Expectations for NBIX FY2025 Earnings - MarketBeat
Assenagon Asset Management S.A. Reduces Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine's CRENESSITY Breakthrough Featured in Major Endocrinology Journal Special Issue - StockTitan
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock - MSN
Neurocrine Bio stock retains outperform rating on robust pipeline - MSN
Avanza Fonder AB Invests $1.80 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Kyle Gano Sells 65,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-15-2023 08 - Marketscreener.com
Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock By Investing.com - Investing.com UK
How To Trade (NBIX) - Stock Traders Daily
Endometriosis Pipeline 2024: Detailed Clinical Trials - openPR
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Burney Co. - MarketBeat
Neurocrine Sues to Clear New Drug of Spruce's Patent 'Ransom' - Bloomberg Law
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $164.81 Consensus PT from Brokerages - MarketBeat
40 Under 40: Ashley Allan, Neurocrine Biosciences - MM+M Online
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - GlobeNewswire
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio - The Manila Times
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
0.79%
0.02%
자본화:
|
볼륨(24시간):